跳至主要内容
临床试验/ACTRN12620000386932
ACTRN12620000386932进行中(未招募)3 期

Benefits and safety of IRon supplementation with MAlaria chemoprevention to children in Malawi (IRMA) - A randomised controlled trial

College of Medicine, University of Malawi0 个研究点目标入组 2,168 人开始时间: 2020年3月20日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
2,168

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
6 Months 至 6 Months(—)
性别
All

入选标准

  • 1.Infants aged 6 months (+/- 14 days) at the time of randomisation
  • 2.Has a legally acceptable guardian/representative capable of understanding the informed consent document and providing consent on the participant’s behalf

排除标准

  • 1.Severe anaemia (Hb<7g/dL) or
  • 2.Current infective illness with fever (respiratory infection, diarrhoea, malaria); however, children will be screened again after recovery and recruited as long as they meet the age eligibility criteria at second screening
  • 3.Severe malnutrition (weight-for-length z-score<-3);
  • 4.Established diagnosis of haemoglobinopathy (e.g. sickle cell disease, beta thalassaemia major, HbE-beta thalassaemia).
  • 5.Legal guardian unwilling or unable to provide written informed consent
  • 6.Known congenital anomaly, developmental disorder or severe developmental delay
  • 7.Children with physical or behavioural problems that will make it impossible to test the child
  • 8.Children of multiple birth e.g. twin, triplets etc.
  • 9.Currently consuming MNPs e.g. from the National MNP programme

研究者

相似试验